Henlix Biotech Inc., an innovative biopharmaceutical company, was co-founded by two American biopharmaceutical veterans, Dr. Scott Liu and Dr. Weidong Jiang in October 2010, in Taiwan and expanded its research site in the San Francisco Bay Area. The company specializes in the discovery and development of innovative monoclonal antibody therapeutics, bi-specific antibodies and antibody drug conjugates (ADCs) by using state of the art technologies. With its core mission in making quality antibody-based therapeutics available and affordable to all patients in need worldwide, Henlix aims to become a trusted leading international biopharmaceutical company with a significant global impact.

Efficient R&DIndependent innovationPeople-oriented

To date, Henlix has several innovative antibody-based therapeutics candidates in the pipeline; the lead product has entered a Phase I clinical trial in 2016. The company targets to file at least 1 IND per year. Henlix has established a state of the art antibody discovery and development engine to accelerate multiple promising novel antibody candidates to the clinic in a cost-effective manner. Henlix emphasizes on teamwork, cares for the growth and development of each employee, endeavors to construct a fair and just, as well as positive working environment, so as to create a productive work environment for the employees' career growth.

Our Team

劉世高 博士


Co-founder / Chief Executive Officer

  • Ph.D. / Department of Biology, Purdue University
  • postdoctoral fellow / Stanford University
  • iMBA courses / Syracuse University
  • Vice President / UBI
  • QC Director / Bristol-Myers Squibb and Amgen

姜偉東 博士


President / Chief Scientific Officer

  • MS / Chinese Academy of Sciences
  • Ph.D. / University of Giessen, Germany
  • Post-doctoral / University of California
  • Senior scientist and directors / ChemGenics (Millennium), Microcide, Applied Mol, Evolution (Eli Lilly), Vasgene, and Catalyst Biosciences




  • MBA / Grand Canyon University (Phoenix)
  • CIO / Industrial Bank of Taiwan Securities Co. Ltd
  • CEO / Group of Investment management business / JihSun Financial Holding company.
  • CSO, CIO / Masterlink Securities Corp.

許文峰 博士


VP / Product Development

  • Ph.D. in Molecular Biology / Shanghai Institute of Biochemistry, Chinese Academy of Science
  • postdoctoral study at University of Washington in Seattle
  • Principal Scientist / ZymoGenetics Inc.
  • Director / Molecular Immunology / Novo Nordisk Research Center
  • Associate Director / Bioanalytical Science for Cancer Immunotherapy / Genentech



January 2020

TFDA IND submission of HLX56 (anti-DR4) was completed.


September 2019

Shanghai Henlius Biotech Co., Ltd. was listed on the main board of the Hong Kong Stock Exchange on 2019/9/25, stock code 2696

September 2019

HLX55(anti-cMET) has been approved by TFDA to conduct the first-in-human Phase I study in Taiwan.

August 2019

HLX10 has been approved by TFDA to conduct a Phase II HBV study in Taiwan.

July 2019

Recruitment of HLX07 FIH phase I trial was completed.

June 2019

TFDA and NMPA IND submission of HLX55 (anti-cMET) was completed.

May 2019

汉利康® (rituximab injection) was granted New Drug Application (NDA) approval by the NMPA in February 2019, which is the first biosimilar drug approved in China in accordance with the Biosimilar Guidelines.

April 2019

IND submission of HLX10 phase 2 HBV trial was completed.


July 2018

HLX20 (PD-L1) has been approved to conduct first in human trial clinical study by China Food and Drug Administration.

June 2018

Henlix Biotech Co.,Ltd. is a 100% wholly-owned subsidiary of Shanghai Henlius Biotech, Inc.


November 2017

HLX06 Investigational New Drug Application (IND) was approved by Taiwan, US and Chinese Food and Drug Administration, Phase I trial was started in December 2017.

October 2017

HLX10 has been approved to conduct first in human trial clinical study by Taiwan, US, and China Food and Drug Administration.

October 2017

The Capital of Henlix Biotech Co., Ltd. is 0.78 Billions NTD.


December 2016

Henlix Biotech Co., Ltd. has been awarded the 13th National Innovation Award for Development and Application of an Innovative Monoclonal Antibody HLX07 for Cancer Therapy in the Pharmaceutical and New Medical Technology Category by the Institute for Biotechnology and Medicine Industry.

June 2016

HLX07 Investigational New Drug Application (IND) was approved by Taiwan, US and Chinese Food and Drug Administration, Phase I trial was started in August 2016.

January 2016

In January 2016, Henlix completed financing of 258,000,000 NT dollars, with the actual receipt capital of 663,000,000 NT dollars.


June 2015

In June 2015, Henlix's authorized capital was 100,000,000 NT dollars, with actual receipt capital of 404,000,000 NT dollars.


November 2014

In November 2014, Henlix completed financing of 240,000,000 NT dollars, under 96.4% of holdings, by U.S. Henlix.

July 2014

In July 2014, Henlix positioned its research and development focus on innovative monoclonal antibody development.

April 2014

In April 2014, Henlix Biotech Inc. was restructured into Henlix Biotech Ltd


March 2013

In March 2013, Henlix completed financing of 8,780,000 NT dollars, with actual receipt capital of 8,880,000 NT dollars.


January 2012

In 2012, Henlix started to provide R&D service of innovative monoclonal antibody for U.S Henlix and Shanghai Henlius


March 2011

In 2011, Henlix cooperated with the Industry-Academy Cooperation Incubation Center of the Taipei Medical College to conduct the research project of innovative monoclonal antibodies.


October 2010

In October 2010, the Henlix Biotech Inc.was founded in Taiwan.